Indian Pharma Companies Launch Generic Semaglutide Post Patent Expiry

India Pharma Outlook Team | Monday, 23 March 2026

Indian Pharma Companies have kicked off an aggressive race in generic semaglutide after the patent for the blockbuster diabetes and weight-loss drug expired on March 20, 2026.

Nearly ten drugmakers, including Dr. Reddy’s Laboratories, Sun Pharma, and Zydus Lifesciences, have launched their own versions, targeting what is projected to become a INR 12,000 crore market over the next five years.

The launch wave includes self-developed formulations from Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals, while Glenmark, Eris Lifesciences, Lupin, and USV have entered through licensing agreements. Even as competition heats up in generic semaglutide, pharma stocks declined, with the Nifty Pharma index dropping 1.15 percent in early trade and most constituents trading lower.

Companies are differentiating through approvals and partnerships. Zydus, Alkem, and Sun Pharma have secured approvals for both type 2 diabetes and obesity, expanding their addressable market. Dr. Reddy’s and Natco are currently focused on diabetes alone. Dr. Reddy’s has licensed its product to USV and Torrent, while Zydus has partnered with Lupin and Torrent for its reusable pen. Natco has tied up with Glenmark and Eris Lifesciences for vial and pen formats.

Also Read: Ozempic Patent Expiry Drives Surge in Pharma Stocks Ahead of Launch

Innovation in delivery is shaping the market. While most players offer disposable pens, Zydus and Alkem have introduced reusable pens that cut costs and allow flexible dosing, especially in early treatment stages. Torrent Pharmaceuticals has moved ahead in the oral semaglutide segment with a tablet launch, although analysts remain cautious due to weak global trends in similar products.

Pricing has become the biggest competitive lever. Most companies have priced disposable pens at INR 4,200–INR 5,200 per month for diabetes. Alkem has taken a disruptive approach, offering its version at around INR 2,000 per month. For obesity, Sun Pharma’s product is priced near INR 8,000 monthly, while Alkem offers a similar treatment at roughly INR 3,500. Reusable pens from Zydus and Alkem range between INR 1,800–INR 2,200 for diabetes and INR 3,500–INR 5,500 for obesity. The vial format remains the cheapest at about INR 1,290 per month.

These prices are sharply lower than the innovator drugs, which cost over INR 11,000 per month for diabetes and INR 16,000 for weight loss.

Analysts expect strong growth driven by affordability and rising demand. Zydus is seen benefiting from its differentiated devices and partnerships, while Alkem could gain volume share through aggressive pricing. Dr. Reddy’s and Sun Pharma are also well placed due to their scale and distribution.

However, growth in oral semaglutide may stay limited, and vial-based treatments are expected to hold less than 30 percent market share as patients and doctors continue to prefer pen-based delivery.

Market Size & Growth

Indian semaglutide market expected to cross INR 12,000 crore in 5 years
Current GLP-1 market estimated at INR 1,000–INR 1,200 crore
Market projected to grow 4–5x by 2030
Global semaglutide market expected to exceed $30 billion by 2026

Industry Participation

Around 10 Indian pharma companies have already launched generics
Over 50 branded generic versions expected in the market
Some estimates suggest 40+ companies developing 50+ products

Pricing Trends

Innovator drug price:
- INR 11,000+/month (diabetes)
- INR 16,000/month (weight loss)
Generic pricing:
- Disposable pens: INR 4,200–INR 5,200/month
- Alkem pricing: ~INR 2,000/month
- Obesity treatment: INR 3,500–INR 8,000/month
- Reusable pens: INR 1,800–INR 2,200/month
- Vials: ~INR 1,290/month
Price drop: up to 90 percent reduction vs innovator drugs

Demand & Patient Base